PhenomeX Past Earnings Performance
Past criteria checks 0/6
PhenomeX's earnings have been declining at an average annual rate of -37.4%, while the Life Sciences industry saw earnings growing at 20.7% annually. Revenues have been growing at an average rate of 8.8% per year.
Key information
-37.4%
Earnings growth rate
65.0%
EPS growth rate
| Life Sciences Industry Growth | 21.5% |
| Revenue growth rate | 8.8% |
| Return on equity | -111.9% |
| Net Margin | -173.4% |
| Last Earnings Update | 30 Jun 2023 |
Recent past performance updates
Recent updates
Analyst Forecasts Just Became More Bearish On PhenomeX Inc. (NASDAQ:CELL)
May 16
PhenomeX Inc.'s (NASDAQ:CELL) Subdued P/S Might Signal An Opportunity
Apr 17Analysts Just Made A Major Revision To Their Berkeley Lights, Inc. (NASDAQ:BLI) Revenue Forecasts
Aug 15Mehul Joshi joins Berkeley Lights as CFO
Jul 25Berkeley Lights Grows Revenue But Operating Losses Mount
Dec 09Are Investors Undervaluing Berkeley Lights, Inc. (NASDAQ:BLI) By 49%?
Nov 07Berkeley Lights: Short Seller Report Raises A Few Legitimate Questions
Sep 23Berkeley Lights: Optofluidic Technology Presents Strong Upside, May Redefine Therapeutic Development
Jun 09Berkeley Lights Q1 2021 Earnings Preview
May 10Revenue & Expenses BreakdownBeta
How PhenomeX makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 23 | 72 | -125 | 110 | 35 |
| 31 Mar 23 | 77 | -100 | 104 | 44 |
| 31 Dec 22 | 79 | -98 | 95 | 53 |
| 30 Sep 22 | 84 | -86 | 82 | 61 |
| 30 Jun 22 | 87 | -85 | 75 | 68 |
| 31 Mar 22 | 87 | -78 | 72 | 63 |
| 31 Dec 21 | 85 | -72 | 69 | 59 |
| 30 Sep 21 | 84 | -66 | 63 | 57 |
| 30 Jun 21 | 78 | -54 | 55 | 51 |
| 31 Mar 21 | 69 | -50 | 45 | 49 |
| 31 Dec 20 | 64 | -43 | 38 | 47 |
| 30 Sep 20 | 59 | -35 | 31 | 43 |
| 30 Jun 20 | 57 | -32 | 26 | 43 |
| 31 Mar 20 | 58 | -26 | 24 | 41 |
| 31 Dec 19 | 57 | -21 | 22 | 38 |
| 31 Dec 18 | 31 | -27 | 15 | 29 |
Quality Earnings: CELL is currently unprofitable.
Growing Profit Margin: CELL is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CELL is unprofitable, and losses have increased over the past 5 years at a rate of 37.4% per year.
Accelerating Growth: Unable to compare CELL's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CELL is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (-11.4%).
Return on Equity
High ROE: CELL has a negative Return on Equity (-111.91%), as it is currently unprofitable.